Last updated: April 15, 2024
Sponsor: Steen Hvitfeldt Poulsen
Overall Status: Active - Recruiting
Phase
N/A
Condition
Heart Defect
Amyloidosis
Congestive Heart Failure
Treatment
Dobutamine stress echocardiography
Clinical Study ID
NCT06372301
1-10-72-179-23
Ages > 65 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- ATTRwt, diagnosis confirmed by 99mtc-3,3-Diphosphono-1,2-Propanodicarboxylic Acid (DPD) scintigraphy, genetic testing, and/or endomyocardial biopsy.
- Symptomatic patients (New York Heart Association > class I) treated with loopdiuretics.
- LF/LG AS: Defined as, aortic valve area ≤ 1 cm2 and mean gradient < 40 mmHg, and SVI ≤35 ml/m2.
- Age ≥ 65 years.
- Oral and written informed consent.
Exclusion
Exclusion Criteria:
- Other significant valvular disease.
- Known severe coronary artery diseases: left main stem stenosis or 3-vessel disease, orrecent acute myocardial infarction (< 4 weeks).
- Contraindications to the use of dobutamine: Known allergy to dobutamine or sulfite,phaeochromocytoma or ventricular tachycardia (VT).
Study Design
Total Participants: 24
Treatment Group(s): 1
Primary Treatment: Dobutamine stress echocardiography
Phase:
Study Start date:
April 02, 2024
Estimated Completion Date:
April 01, 2026
Study Description
Connect with a study center
Department of Cardiology, Aarhus University Hospital
Aarhus, 8200
DenmarkActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.